MedTrace Logo

Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma

NCT03982849 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-02-12

No results posted yet for this study

Summary

A randomized clinical trial will be done on 92 patients , randomly divided into two groups by lottery method to compare the efficacy and safety of topical silymarin cream 0.7% with topical 4% hydroquinone cream. Patients will be treated for 3 months and for the next 3 months will be followed up for relapse of melasma.

Conditions

  • Melasma

Interventions

DRUG

Hydroquinone 4% Cream

Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.

DRUG

silymarin 0.7% cream

Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.

Sponsors & Collaborators

  • Islamabad Medical and Dental College

    lead OTHER

Principal Investigators

  • Sumaira Abdullah, MBBS, MCPS, MD · Senior Registrar in Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2019-12-31
Completion
2020-01-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982849 on ClinicalTrials.gov